2026-02-12, 2:21:05 p.m.
VANCOUVER, British Columbia — February 12, 2026 — Leads & Copy — NervGen Pharma Corp. (TSXV: NGEN) (NASDAQ: NGEN) has announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026.
The company has engaged an executive search firm to find a successor. Adams will continue in an advisory role after his retirement to help with the transition.
Adam Rogers, MD, President and Chief Executive Officer of NervGen, thanked Adams for his leadership and dedication. Rogers noted Adams’ role during a critical phase of the company. He also expressed gratitude for Adams’ integrity and commitment.
Adams stated he was honored to have served as CFO and to have contributed to the company’s accomplishments. He said he was pleased to have helped guide the company’s transformation to a Nasdaq-listed entity in late-stage development for NVG-291, a therapeutic candidate for spinal cord injury.
Adams added that he is proud of the financial and operational foundation built at NervGen and believes the company is well-positioned. He looks forward to supporting NervGen during the transition.
NervGen Pharma is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions.
The company’s lead therapeutic candidate, NVG-291, is a subcutaneously administered peptide. It was evaluated in the Phase 1b/2a CONNECT SCI Study in individuals with chronic SCI and is currently being studied in individuals with subacute SCI, alongside preparation for a Phase 3 clinical trial in chronic SCI. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI.
Through NVG-291 and its next-generation candidate, NVG-300, NervGen aims to transform the treatment of neurotraumatic and neurologic conditions.
Source: NervGen Pharma
